Use of ctDNA in identifying an actionable BRAF mutation in stage 4 metastatic melanoma

被引:0
|
作者
Bennett, Charlotte [1 ]
Morgan, Sian [2 ]
Aboud, Karam [1 ]
Frazer, Ricky Dylan [1 ]
机构
[1] Velindre Univ NHS Trust, Oncol, Cardiff, Wales
[2] All Wales Med Genet Serv, Oncol, Cardiff, Wales
关键词
Skin cancer; Oncology; Malignant disease and immunosuppression; Cancer intervention;
D O I
10.1136/bcr-2022-254268
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The identification of genetic variants in melanoma has enabled the development of targeted therapies. Under the National Institute for Health and Care Excellence (NICE) guidance, patients with BRAF V600E variant are eligible for BRAF and MEK inhibitor therapy. For those with advanced or highly symptomatic disease, a rapid response to treatment is often seen. Current practice relies on tissue biopsy to perform immunohistochemistry (IHC) or next generation sequencing (NGS) to identify these variants; however, this can take up to 2 weeks. In patients with widespread disease, rapid initiation of treatment can be lifesaving.We describe a case in which hotspot circulating tumour DNA (ctDNA) analysis confirmed BRAF variant 6 days prior to biopsy results. This was utilised to expedite treatment initiation and symptomatically, the patient had initial improvement within a few days.This article demonstrates the potential value of ctDNA analysis and the need for further research into this as an alternative to NGS for patients with rapidly progressive disease.
引用
收藏
页数:3
相关论文
共 50 条
  • [21] The Clinical Significance of BRAF Mutation in a Clinic-Based Metastatic Melanoma Cohort
    Ekedahl, H.
    Cirenajwis, H.
    Harbst, K.
    Carneiro, A.
    Nielsen, K.
    Olsson, H.
    Lundgren, L.
    Ingvar, C.
    Jonsson, G.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 : 42 - 42
  • [22] BRAF mutation by age-decade and body mass index in metastatic melanoma
    Menzies, A. M.
    Visintin, L.
    Chatfield, M. D.
    Carlino, M. S.
    Howle, J. R.
    Scolyer, R. A.
    Thompson, J. F.
    Kefford, R. F.
    Long, G. V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [23] Patients with stage IV melanoma with BRAF mutation - immunotherapy or BRAF and MEK inhibitors in first line therapy?
    Cybulska-Stopa, Bozena
    Ziobro, Marek
    ONCOLOGY IN CLINICAL PRACTICE, 2018, 14 : A9 - A12
  • [24] Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre
    Potter, Alison J.
    Colebatch, Andrew J.
    Rawson, Robert, V
    Ferguson, Peter M.
    Cooper, Wendy A.
    Gupta, Ruta
    O'Toole, Sandra
    Saw, Robyn P. M.
    Ch'ng, Sydney
    Menzies, Alexander M.
    Long, Georgina, V
    Scolyer, Richard A.
    PATHOLOGY, 2022, 54 (05) : 526 - 532
  • [25] Response of metastatic acral melanoma with exon 11 BRAF G469A mutation to BRAF/MEK inhibition
    Julius, Katharina
    Kromer, Christian
    Schnabel, Viktor
    Vlahova, Lyubomira
    Kitz, Julia
    Schoen, Michael P.
    Sahlmann, Carsten-Oliver
    Kretschmer, Lutz
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 (04): : 528 - +
  • [26] A rare BRAF T599dup mutation conferring sensitivity to BRAF inhibitor in a patient with metastatic melanoma
    Marchand, A.
    Tallet, A.
    Collin, C.
    Cormier, B.
    Venel, Y.
    Miquelestorena-Standley, E.
    Machet, L.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (02) : 528 - 529
  • [27] Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma
    Ziogas, Dimitrios C.
    Konstantinou, Frosso
    Bouros, Spyros
    Gogas, Helen
    EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (01) : 53 - 62
  • [28] Use of Cobas 4800 BRAF mutation test for the analysis of BRAF V600 mutations in cytological samples (CS) from metastatic melanoma (MM)
    Martin-Algarra, Salvador
    Labiano, Tania
    Ignacio Echeveste, Jose
    Gomez, Nerea
    Montanana, Myriam
    Aguirre, Mercedes
    Eugenia Echarri, Maria
    Sanmamed, Miguel F.
    Gurpide, Alfonso
    Luis Perez-Gracia, Jose
    Idoate, Miguel A.
    Lozano, Maria D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [29] Analysis of BRAF, NRAS and PI3K mutation in primary and metastatic melanoma
    Libra, Massimo
    Malaponte, Grazia
    Callari, Daniela
    D'Assoro, Antonio
    Travali, Salvatore
    Mazzarino, Maria C.
    McCubrey, James A.
    Stivala, Franca
    CANCER RESEARCH, 2006, 66 (08)
  • [30] Rescue surgery in a patient with metastatic melanoma and BRAF V600E mutation
    de Miguel, Maite
    Jimeno, Jaime
    Vidal, Joana
    Segura, Sonia
    Lorente, Leyre
    CIRUGIA ESPANOLA, 2018, 96 (10): : 665 - 666